Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3386f5906dc1bdc9c934203594712c66 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
filingDate |
2006-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9df43eceb7fd8c0a573d128b12f46f4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f9be3c43dba0149f4bc75db2a34189f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b7c96ce2258b72f2d878b09ce939c4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e6f5d029f0eca785c788d77b2640e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e40a2f454cc686dbc3f04868c0f1bd1c |
publicationDate |
2008-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20080025373-A |
titleOfInvention |
Treatment of Pompe disease with 1-deoxynojirimycin and derivatives |
abstract |
The present invention provides a method of increasing the activity of a mutant or wild type α-glucosidase enzyme in vitro and in vivo by contacting the α-glucosidase enzyme with a specific pharmaceutical chaperone that is a 1-deoxynojirimycin derivative. do. The present invention also provides a method of treating Pompe disease by administration of a small chaperone molecular compound that is a 1-deoxynojirimycin derivative. The 1-deoxynojirimycin derivative is substituted at the N or Cl position. Combination therapy of alternative α-glucosidase genes or enzymes is also provided. |
priorityDate |
2005-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |